Ignite Creation Date:
2024-05-06 @ 2:30 PM
Last Modification Date:
2024-10-26 @ 1:31 PM
Study NCT ID:
NCT04331626
Status:
UNKNOWN
Last Update Posted:
2020-04-02
First Post:
2020-03-31
Brief Title:
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-04
Start Date Type:
ESTIMATED
Primary Completion Date:
2022-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-04
Completion Date Type:
ESTIMATED
First Submit Date:
2020-03-31
First Submit QC Date:
March 31 2020
Study First Post Date:
2020-04-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-03-31
Last Update Post Date:
2020-04-02
Last Update Post Date Type:
ACTUAL